Skip to main content

Treatment Clinical Trials for Myelodysplastic/Myeloproliferative Disease

Review the myelodysplastic/myeloproliferative disease treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 56

A Randomized Study of ASTX727 with or without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Status: Active
Location: 25 locations
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Status: Active
Location: 19 locations
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Status: Active
Location: 18 locations
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Status: Active
Location: 10 locations
A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Active
Location: 10 locations
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: 11 locations
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Status: Active
Location: 7 locations
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Status: Active
Location: 6 locations
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 4 locations
Ivosidenib and Venetoclax with or without Azacitidine in Treating Patients with IDH1 Mutated Hematologic Malignancies
Status: Active
Location: 4 locations
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Status: Active
Location: 3 locations
Low-Dose Decitabine and Venetoclax for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
Status: Active
Location: 2 locations
A Study of BGB-11417 in Participants With Myeloid Malignancies
Status: Active
Location: 2 locations
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
Status: Active
Location: 2 locations
Tagraxofusp Maintenance Therapy to Prevent Relapse in Patients with CD 123+ Myelofibrosis, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, or Acute Myeloid Leukemia who have Undergone a Stem Cell Transplant
Status: Active
Location: 2 locations
Avapritinib in Combination with Decitabine for the Treatment of Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
Status: Active
Location: 2 locations
Selumetinib and Azacitidine in Treating Patients with Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, and Myelofibrosis
Status: Active
Location: 2 locations
Cytokine-Induced Memory-Like Natural Killer Cell Therapy with interlekin-2 after Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with Measurable Residual Disease
Status: Active
Location: 2 locations
CD4CAR T Cell Therapy for the Treatment of Patients with Relapsed or Refractory CD4 Positive CMML
Status: Active
Location: 2 locations
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Location: 2 locations
Q702 for the Treatment of Patients with Hematologic Malignancies
Status: Active
Location: 2 locations
Ruxolitinib before, during and after Hematopoietic Cell Transplant in Older Patients with Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Decitabine with Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Cladribine, Low Dose Cytarabine, Venetoclax, and Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia or Myelodysplastic Syndrome/Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas